Is onabotulinumtoxinA (Botox) an appropriate off‑label treatment for chronic abdominal pain in adults refractory to standard therapy, and what dosing regimen is recommended?

Use of Botulinum Toxin for Chronic Abdominal Pain

Botulinum toxin (Botox) is not recommended as a standard treatment for chronic abdominal pain in adults, as there is insufficient evidence to support its efficacy and safety for this indication, and it lacks FDA approval for gastrointestinal pain management. 1

Evidence-Based Treatment Approach for Chronic Abdominal Pain

The 2021 AGA guidelines on chronic gastrointestinal pain in disorders of gut-brain interaction do not include botulinum toxin among recommended therapies. 1 Instead, the guidelines emphasize:

First-Line Management

• Opioids should never be prescribed for chronic gastrointestinal pain due to disorders of gut-brain interaction. 1
• Nonpharmacologic therapies should be considered routinely and introduced early in care. 1
• Optimize peripherally-acting medications first, including antispasmodics, peppermint oil, secretagogues (linaclotide, tenapanor), and 5-HT receptor drugs depending on the specific disorder. 1

Neuromodulator Therapy (Preferred Pharmacologic Approach)

When pain persists despite conservative management, gut-brain neuromodulators are the evidence-based pharmacologic choice: 1

• Tricyclic antidepressants (TCAs) rank first for abdominal pain relief in network meta-analyses and should be started at low doses with gradual titration. 1
• SNRIs (serotonin-norepinephrine reuptake inhibitors) like duloxetine have greater analgesic effects than SSRIs due to norepinephric activity. 1
• SSRIs alone are not recommended for pain management in these conditions. 1

Limited Evidence for Botulinum Toxin in Abdominal Pain

Preclinical and Case Report Data Only

• Animal studies show intrathecal botulinum toxin (2 U/kg) reduced abdominal pain behaviors in experimental peritonitis and colitis models, but this was spinal administration, not clinically applicable. 2
• One case report described successful celiac plexus botulinum toxin injection for cancer-related abdominal pain, but this represents anecdotal evidence in a highly specific scenario (post-surgical adhesions in a cancer survivor). 3
• Gastroparesis studies (not chronic abdominal pain per se) showed mixed results with pyloric botulinum toxin injections, with no large controlled trials confirming efficacy. 4

Negative Evidence

• A 2025 randomized controlled trial of botulinum toxin (100 units) injected into pelvic floor muscles for chronic pelvic pain showed no significant benefit over placebo for pain reduction (33% vs 20% responders, p=0.19). 5

FDA-Approved Indications for Botulinum Toxin

Botulinum toxin has no FDA approval for chronic abdominal pain or gastrointestinal disorders. 1 Approved indications relevant to pain include:

• Chronic migraine (onabotulinumtoxinA is safe and effective). 1
• Spasticity in adults (upper and lower extremity). 1
• Overactive bladder (intradetrusor injection, 100 U, as third-line therapy after careful patient selection). 1
• Cervical dystonia and blepharospasm. 1

Clinical Pitfalls to Avoid

• Do not use botulinum toxin off-label for chronic abdominal pain without compelling evidence, as this exposes patients to potential adverse effects (dysphagia, muscle weakness, hypersensitivity reactions) without proven benefit. 1
• Recognize that abdominal pain in disorders of gut-brain interaction requires addressing central sensitization, not just peripheral mechanisms—botulinum toxin's mechanism does not target central pain processing. 1
• Avoid the temptation to try unproven therapies when evidence-based neuromodulators (TCAs, SNRIs) and nonpharmacologic approaches remain underutilized. 1

Recommended Algorithm

For chronic abdominal pain refractory to standard therapy:

1. Confirm the diagnosis is a disorder of gut-brain interaction (IBS, functional dyspepsia, centrally mediated abdominal pain syndrome). 1
2. Optimize peripherally-acting medications based on the specific disorder (antispasmodics, linaclotide for IBS-C, ramosetron/alosetron for IBS-D). 1
3. Initiate gut-brain neuromodulators (start with TCAs at low doses, titrate based on response). 1
4. Incorporate nonpharmacologic therapies (cognitive-behavioral therapy, gut-directed hypnotherapy). 1
5. Botulinum toxin should not be considered given the lack of evidence and availability of superior alternatives. 1